ERK inhibition with PD184161 mitigates brain damage in a mouse model of stroke

Journal of Neural Transmission

Volumn 121, Issue 5, 2014, Pages 543-547

  Gladbach, Amadeus ^a,b   Van Eersel, Janet ^a,b   Bi, Mian ^a,b   Ke, Yazi D ^a,b   Ittner, Lars M ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

ERK; Glutamate; Immediate early gene; MEK inhibitor; PD184161; Stroke

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BICUCULLINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PD 184161; PENTETRAZOLE; PROTEIN FOS; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG; 2-(2-CHLORO-4-IODOPHENYLAMINO)-N-CYCLOPROPYLMETHOXY-3,4-DIFLUORO-5-BROMOBENZAMIDE; ANILINE DERIVATIVE; BENZAMIDE DERIVATIVE; ENZYME INHIBITOR; GLUTAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; BRAIN INFARCTION SIZE; BRAIN PROTECTION; BRAIN SIZE; CELL DEATH; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXCITOTOXICITY; GENE EXPRESSION; IMMEDIATE EARLY GENE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL CULTURE; NERVE CELL NECROSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RNA PURIFICATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; C57BL MOUSE; CELL CULTURE; CEREBRAL ARTERY DISEASE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STROKE;

ANILINE COMPOUNDS; ANIMALS; BENZAMIDES; BRAIN; CELL DEATH; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GLUTAMIC ACID; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE, INBRED C57BL; NEURONS; STROKE;

EID: 84901334425     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1138-2     Document Type: Article

References (16)

1. Alessandrini A, Namura S, Moskowitz MA, Bonventre JV (1999) MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci USA 96(22):12866-12869 (Pubitemid 29513594)
2. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408(3):297-315. doi:10.1042/BJ20070797
3. Connolly ES Jr, Winfree CJ, Stern DM, Solomon RA, Pinsky DJ (1996) Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. Neurosurgery 38(3):523-531 discussion 532
4. Donnan GA, Fisher M, Macleod M, Davis SM (2008) Stroke. Lancet 371(9624):1612-1623. doi:S0140-6736(08)60694-710.1016/S0140-6736(08)60694-7
5. Fath T, Ke YD, Gunning P, Gotz J, Ittner LM (2009) Primary support cultures of hippocampal and substantia nigra neurons. Nat Protoc 4(1):78-85
6. Hardingham GE, Arnold FJ, Bading H (2001) A calcium microdomain near NMDA receptors: on switch for ERK-dependent synapse-to-nucleus communication. Nat Neurosci 4(6):565-566. doi:10.1038/88380 (Pubitemid 32507368)
7. Henriksson M, Stenman E, Vikman P, Edvinsson L (2007) MEK1/2 inhibition attenuates vascular ETA and ETB receptor alterations after cerebral ischaemia. Exp Brain Res 178(4):470-476. doi:10.1007/s00221-006-0753-7 (Pubitemid 46569887)
8. Ittner LM, Koller D, Muff R, Fischer JA, Born W (2005) The N-terminal extracellular domain 23-60 of the calcitonin receptor-like receptor in chimeras with the parathyroid hormone receptor mediates association with receptor activity-modifying protein 1. Biochemistry 44(15):5749-5754 (Pubitemid 40525111)
9. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142(3):387-397. doi:S0092-8674(10)00726-910.1016/j. cell.2010.06.036
10. Maddahi A, Edvinsson L (2008) Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway. BMC Neurosci 9:85. doi:10.1186/1471-2202-9-85
11. Maddahi A, Edvinsson L (2010) Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway. J Neuroinflammation 7:14. doi:10.1186/1742-2094-7-14
12. Namura S, Iihara K, Takami S, Nagata I, Kikuchi H, Matsushita K, Moskowitz MA, Bonventre JV, Alessandrini A (2001) Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci USA 98(20):11569-11574. doi:10.1073/pnas.181213498 (Pubitemid 32928769)
13. Simon RP, Swan JH, Griffiths T, Meldrum BS (1984) Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 226(4676):850-852
14. Wang X, Wang H, Xu L, Rozanski DJ, Sugawara T, Chan PH, Trzaskos JM, Feuerstein GZ (2003a) Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. J Pharmacol Exp Ther 304(1):172-178. doi:10.1124/jpet.102.040246 (Pubitemid 36008925)
15. Wang Z, Chen X, Zhou L, Wu D, Che X, Yang G (2003b) Effects of extracellular signal-regulated kinase (ERK) on focal cerebral ischemia. Chin Med J (Engl) 116(10):1497-1503 (Pubitemid 37461663)
16. Wang ZQ, Wu DC, Huang FP, Yang GY (2004) Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia. Brain Res 996(1):55-66